Safety and effectiveness of eculizumab in Japanese patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: interim analysis of post-marketing surveillance data

被引：0
|
作者：
Nakashima, I. [1 ]
Hoshino, Y. [2 ]
Okamura, K. [2 ]
Kikui, H. [2 ]
机构：
[1] Tohoku Med & Pharmaceut Univ, Div Neurol, Sendai, Miyagi, Japan
[2] Alex Pharma GK, Tokyo, Japan
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P973
引用
收藏
页码：791 / 792
页数：2
相关论文
共 50 条
  • [1] Safety and Effectiveness of Eculizumab in Japanese Patients With Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study
    Nakashima, Ichiro
    Hoshino, Yo
    Okamura, Kazumi
    Kikui, Hidekazu
    Fujihara, Kazuo
    Edwards, Yuriy
    NEUROLOGY, 2022, 99 (23) : S2 - S3
  • [2] Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+NMOSD): Interim Analysis of a Post-Marketing Surveillance Study
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP25 - NP25
  • [3] Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance Study (P1-1.Virtual)
    Nakashima, Ichiro
    Hoshino, Yo
    Okamura, Kazumi
    Kikui, Hidekazu
    Fujihara, Kazuo
    NEUROLOGY, 2022, 98 (18)
  • [4] Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan
    Nakashima, Ichiro
    Nakahara, Jin
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2023, 16
  • [5] Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 6-month Interim Analysis of Post-marketing Surveillance
    Yamamura, Takashi
    Isobe, Noriko
    Kawachi, Izumi
    Nohara, Chiyoko
    Miyazaki, Yusei
    Tomita, Minami
    Tsumuraya, Takahiko
    Yamashita, Katsuhisa
    Nakahara, Jin
    Nakashima, Ichiro
    Fujihara, Kazuo
    NEUROLOGY AND THERAPY, 2024, 13 (05) : 1361 - 1383
  • [6] Benefit of eculizumab for a broad range of patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from prevent
    Fujihara, K.
    Berthele, A.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Oreja-Guevara, C.
    Palace, J.
    Pittock, S.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Miller, L.
    Tanvir, I.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 447 - 448
  • [7] Eculizumab in AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [8] Eculizumab in AQP4+neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
    Nakahara, J.
    Nakashima, I.
    Yokote, H.
    Manabe, Y.
    Okamura, K.
    Hasegawa, K.
    Fujihara, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 638 - 639
  • [9] Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study
    Palace, J.
    Pittock, S. J.
    Berthele, A.
    Fujihara, K.
    Kim, H. J.
    Levy, M.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K. -C.
    Pace, A.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D. M.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 737 - 738
  • [10] Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study
    Berthele, Achim
    Pittock, Sean J.
    Fujihara, Kazuo
    Kim, Ho Jin
    Levy, Michael
    Palace, Jacqueline
    Nakashima, Ichiro
    Terzi, Murat
    Totolyan, Natalia
    Viswanathan, Shanthi
    Wang, Kai-Chen
    Shang, Shulian
    Yountz, Marcus
    Armstrong, Roisin
    Wingerchuk, Dean M.
    NEUROLOGY, 2020, 94 (15)
12345